1. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, et al. The global distribution and burden of dengue. Nature. 2013;496:504–7. doi: 10.1038/nature12060 .
2. Brady OJ, Gething PW, Bhatt S, Messina JP, Brownstein JS, Hoen AG, et al. Refining the global spatial limits of dengue virus transmission by evidence-based consensus. PLoS Negl Trop Dis. 2012;6:e1760. doi: 10.1371/journal.pntd.0001760 .
3. Capeding MR, Tran NH, Hadinegaro SR et al. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomized, observer-masked, placebo-controlled trial. Lancet 2014;384(9951):1358–65. doi: 10.1016/S0140-6736(14)61060-6 .
4. Villar L, Dayan GH, Arredondo-Garcia JL, Rivera DM, Cunha R, Deseda C, et al. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children and adolescents in aged 9 to 16 years in Latin America. N Engl J Med. 2014;. doi: 10.1056/NEJMoa1411037 .
5. Constenla D, Lefcourt N, Garcia C. Expert Panel on Developing Guidelines for the Estimation of Costs of Dengue in the Latin American and Caribbean Region. In: Proceedings of the workshop on developing regional guidelines of costs of dengue with a focus on the Latin America and Caribbean Region. Available from: http://www.denguevaccines.org/sites/default/files/Proceedings%20Guidelines%20Workshop.pdf . Accessed 11 Aug 2014.